BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12505055)

  • 1. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin.
    Erdös EG; Jackman HL; Brovkovych V; Tan F; Deddish PA
    J Mol Cell Cardiol; 2002 Dec; 34(12):1569-76. PubMed ID: 12505055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A.
    Jackman HL; Massad MG; Sekosan M; Tan F; Brovkovych V; Marcic BM; Erdös EG
    Hypertension; 2002 May; 39(5):976-81. PubMed ID: 12019279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors.
    Chen Z; Tan F; Erdös EG; Deddish PA
    Hypertension; 2005 Dec; 46(6):1368-73. PubMed ID: 16246972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE.
    Deddish PA; Marcic B; Jackman HL; Wang HZ; Skidgel RA; Erdös EG
    Hypertension; 1998 Apr; 31(4):912-7. PubMed ID: 9535414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade.
    Tom B; de Vries R; Saxena PR; Danser AH
    Hypertension; 2001 Jul; 38(1):95-9. PubMed ID: 11463767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of bradykinin and resensitization of its B2 receptor.
    Marcic B; Deddish PA; Jackman HL; Erdös EG
    Hypertension; 1999 Mar; 33(3):835-43. PubMed ID: 10082496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I.
    Greco AJ; Master RG; Fokin A; Baber SR; Kadowitz PJ
    Can J Physiol Pharmacol; 2006 Nov; 84(11):1163-75. PubMed ID: 17218981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor.
    Deddish PA; Marcic BM; Tan F; Jackman HL; Chen Z; Erdös EG
    Hypertension; 2002 Feb; 39(2 Pt 2):619-23. PubMed ID: 11882619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
    van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
    Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.
    Minshall RD; Tan F; Nakamura F; Rabito SF; Becker RP; Marcic B; Erdös EG
    Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of the hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides.
    Paula RD; Lima CV; Britto RR; Campagnole-Santos MJ; Khosla MC; Santos RA
    Peptides; 1999; 20(4):493-500. PubMed ID: 10458520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?
    Tom B; Dendorfer A; Danser AH
    Int J Biochem Cell Biol; 2003 Jun; 35(6):792-801. PubMed ID: 12676166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide.
    Li P; Chappell MC; Ferrario CM; Brosnihan KB
    Hypertension; 1997 Jan; 29(1 Pt 2):394-400. PubMed ID: 9039133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum.
    Minshall RD; Nedumgottil SJ; Igić R; Erdös EG; Rabito SF
    Peptides; 2000 Aug; 21(8):1257-64. PubMed ID: 11035213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of converting-enzyme inhibitors for angiotensin I versus bradykinin hydrolysis reactions.
    Brooks RR; Miller KE; Jones SM; Burns RH; Huang CT
    J Pharm Sci; 1990 May; 79(5):384-8. PubMed ID: 2161922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery.
    Gorelik G; Carbini LA; Scicli AG
    J Pharmacol Exp Ther; 1998 Jul; 286(1):403-10. PubMed ID: 9655885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme.
    Ahmad S; Varagic J; VonCannon JL; Groban L; Collawn JF; Dell'Italia LJ; Ferrario CM
    Biochem Biophys Res Commun; 2016 Sep; 478(2):559-64. PubMed ID: 27465904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinins, receptors, kininases and inhibitors--where did they lead us?
    Erdös EG; Marcic BM
    Biol Chem; 2001 Jan; 382(1):43-7. PubMed ID: 11258670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue.
    Campbell DJ; Duncan AM; Kladis A
    Hypertension; 1999 Aug; 34(2):171-5. PubMed ID: 10454436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
    Hecker M; Blaukat A; Bara AT; Müller-Esterl W; Busse R
    Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.